Abstract
Aims: To compare the efficacy of nivolumab 1mg/kg+ipilimumab 3mg/kg with regorafenib 160mg, cabozantinib 60mg and nivolumab 3mg/kg monotherapy for second-line treatment of advanced hepatocellular carcinoma. Materials & methods: Indirect comparison using network meta-analysis and propensity score weighting. Results:Nivolumab 1 mg/kg + ipilimumab 3 mg/kghad significantly higher objective response rate(median 31.2% [95% credible interval: 19.6-44.5%]) than cabozantinib (4.2% [2.0-6.5%]) and regorafenib (4.8% [1.1-8.3%]), and significantly longer overall survival (cabozantinib: hazard ratio: 0.46 [95% credible interval: 0.27-0.79]; regorafenib: 0.56 [0.32-0.97]). Nivolumab 1 mg/kg + ipilimumab 3 mg/kghad significantly better objective response rate (difference 21.0% [4.5-37.5%]) and overall survival (hazard ratio: 0.58 [0.35-0.96]) than nivolumab monotherapy. Conclusion:Nivolumab 1 mg/kg + ipilimumab 3 mg/kghad a superior efficacy versus cabozantinib 60mg, regorafenib 160mg and nivolumab 3mg/kg monotherapy as second-line therapy foradvanced hepatocellular carcinoma.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call